Prostate Cancer Coverage from Every Angle

Published Medical Literature

Castration-Sensitive Prostate Cancer: The Cost of Overusing Bone-Modifying Agents
Analyzing Surrogate Endpoints for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
PRESTO Results Back Intensification of Androgen Blockade in Some High-Risk Patients
Radium-223 and Prostate Cancer Bone Metastases: Imaging Technique May Predict Benefit
Radioligand in Metastatic Prostate Cancer: Trial Update on Overall Survival
Novel MRI Metric for Predicting Late Toxicity After Radiation Therapy for Prostate Cancer
Common Urologic Medications and Risk for Cognitive Disorders in Patients Treated for Prostate Cancer
Racial Disparities in Prostate Cancer: Researchers Focus on Socioeconomic Risk Factors
Researchers Examine Use of Chinese Herbal Medicines to Treat Prostate Cancer
Serum Biochemical Index: Potential Prognostic Tool in Prostate Cancer
Metastatic Prostate Cancer: Comparing Survival Outcomes With First-Line Therapies
First-Hand Experience With Focal Therapy for Localized Prostate Cancer
Long-Term Decision Regret After Radical Prostatectomy: Patient Survey Findings
Thoughts on Hypofractionation for Prostate Cancer: International Survey Says...
Gene Fusion Research in Prostate Cancer Advances on Two Fronts
Is Biochemical Recurrence a Surrogate for Overall Survival in Localized Prostate Cancer?
Intraprostatic Insertion of Fiducial Marker May Be Safer Than Previously Thought
Can MRI Improve Detection of Clinically Significant Prostate Cancer?
Diagnosing Prostate Cancer: MRI With Artificial Intelligence Versus Clinical Assessment
Can Pembrolizumab Plus Olaparib Improve Survival in Pretreated Metastatic Castration-Resistant Prostate Cancer?
Potential of Quality Indications to Improve Care During Active Surveillance of Low-Risk Prostate Cancer
Researchers Explore New Strategy for Overcoming Cisplatin Resistance in Metastatic Prostate Cancer
Can Machine Learning Help to Overcome Resistance to AR Antagonists in Prostate Cancer?
Treatment Choice, Immunity, Urinary Tract Infection: All Factors in Prostate Cancer Survival?
Study Finds Myeloid-Like Tumor Hybrid Cells May Promote Progression of Prostate Cancer to Bone
Phase II Trial Shows Potential Benefit of PSMA-Targeted Fluorescent Tracer in Prostate Cancer
Effects of Robotic-Assisted Surgery for Prostatectomy on Treatment Centralization and Patient Hospital Choice
Can Combining Transrectal Ultrasound and Pelvic Floor Muscle Exercise Improve Postoperative Urinary Incontinence?
Researchers Shed Light on Heterogeneity and Regulation of PSMA in Metastatic Prostate Cancer
Prostate Cancer in African Americans: Study Focuses on Vitamin D Receptor Function and Genomic Ancestry
Race and Prostate Cancer: Researchers Share New Genetic Findings
Are American Indian/Alaska Native Men Being Screened Adequately for Prostate Cancer?
Can Exposure to Nitrates in Drinking Water Increase the Risk for Prostate Cancer?
Can Deep Learning Provide Assistance in Assessing Treatment Response in Advanced Prostate Cancer?
Using Diffusion-Weighted MRI in Assessing Suspected Prostate Cancer
Active Surveillance: Path of Choice for Many U.S. Patients With Prostate Cancer
Prostate Cancer, Multiple Myeloma, and CML: A Rare Triple Combination in a Single Patient
UK Study Focuses on Outcomes by Therapy After 15 Years of Follow-up
Can the Mark Cuban Cost Plus Drug Company Model Reduce Costs for Patients With Urologic Diseases?
Assessing Patient-Reported Outcomes After Radionuclide Therapy for Prostate Cancer
More MAGNITUDE Results in Prostate Cancer With Niraparib for Additional HRR Alterations
HERO and the Heart: How Cardiovascular Agents Impact the Use of Relugolix in Advanced Prostate Cancer
Novel BRCA2 Mutation Strengthens Evidence for Germline Genetic Testing
MRI or Standard Biopsy: Which Is More Cost-Effective in Prostate Cancer Screening?
IRONMAN: International Registry of Men With Advanced Prostate Cancer
Is Adding Olaparib to Cediranib of Benefit in Metastatic Castration-Resistant Prostate Cancer?
VA Study Addresses the Impact of PSA Screening on Subsequent Metastatic Prostate Cancer
Machine Learning Algorithm: On the Path to Predicting Outcomes From Radical Prostatectomy
Researchers Reveal the Potential of Nitric Oxide in the Treatment of Prostate Cancer
Can a Novel Genetic Scoring Method Predict the Risk for Aggressive Prostate Cancer?
20-Year Experience With Whole Gland Cryoablation in Patients With Prostate Cancer
Are Prostate Tumor Germline Mutations Linked to Genetic Ancestry?
Novel Methylation-Based Biomarkers May Predict Prostate Cancer Mortality
Rezvilutamide or Bicalutamide: Which Is a Better Partner for Androgen-Deprivation Therapy?
Change in Public Messaging May Dispel Common Misconception and Improve Outcomes in Prostate Cancer
Can Drinking Coffee Improve Survival in Prostate Cancer?
Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
Can a Hydrogel Spacer Reduce Rectal Toxicity From Dose-Escalated Radiotherapy for Prostate Cancer?
Study to Compare Radical Prostatectomy Techniques: Focus on Intraoperative Frozen Section
Do Homologous Recombination Deficiency Scores Have Prognostic Value in Aggressive Prostate Cancer?
Radiotherapy for Prostate Cancer and Risk of Second Primary Cancer
Prostate Cancer Risk Prediction Tools and How to Accommodate for Missing Risk Factor Data
Ferroptosis-Related Long Noncoding RNAs: Predictors of Biochemical Recurrence of Prostate Cancer?
Researchers Offer Evidence That Prostate Cancer Biology May Differ by Racial Ancestry
Adding Darolutamide to Standard Treatment in Metastatic, Hormone-Sensitive Prostate Cancer
Enzalutamide Monotherapy: Active Surveillance Alternative in Low- or Intermediate-Risk Prostate Cancer?
Can the Number of Positive Pelvic Lymph Nodes Guide Adjuvant Radiation Therapy for Prostate Cancer?
Oligometastatic Hormone-Sensitive Prostate Cancer: Androgen-Deprivation and Radiation Therapies
High-Frequency Irreversible Electroporation for Localized Prostate Cancer
FSCN1 Protein: Potential Biomarker of Use in Diagnosing and Treating Prostate Cancer?
Patient-Reported Quality-of-Life Changes 15 Years After Treatment for Prostate Cancer
LINC00893: Does It Have a Novel Tumor-Suppressor Role to Play in Prostate Cancer?
Predicting Outcomes in Advanced Prostate Cancer: Focus on Lu-177–PSMA-617 Radioligand Therapy
Does Race Influence Treatment Opportunities for Men With Prostate Cancer?
Can FSH Levels Influence Oncogenic and Cardiovascular Outcomes in Men With Prostate Cancer?
Multimodal Treatment and Mortality Outcomes in High-Risk Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer: Reconsidering the Role of Olaparib
Is Radiotherapy of Benefit for Men With Prostate Cancer and Inflammatory Bowel Disease?
Radioligand Therapy Plus Standard Care for Metastatic Castration-Resistant Prostate Cancer
Swedish Simulation Model Study in Prostate Cancer: Focus on PSA Testing
Prognostic Factors for Decisional Regret Regarding Treatment in Localized Prostate Cancer
PSA Velocity and Disease Progression in Black Versus Non-Hispanic White Men With Prostate Cancer
Potential Role of 11-Ketotestosterone in Castration-Resistant Prostate Cancer
Mortality Risk and PSA Failure in Localized Versus Locally Advanced Prostate Cancer
Environmental Quality and Stage of Prostate Cancer at Diagnosis
Can Genomic Testing Impact Treatment Choice for Low-Risk Prostate Cancer?
Does Race Affect Response to Treatment in Metastatic Castration-Resistant Prostate Cancer?
ctDNA-Targeted Sequencing in Metastatic Prostate Cancer: Real-World Chinese Study
Leuprolide Acetate for Prostate Cancer: Achieving Effective Testosterone Suppression
Is Dietary Acrylamide Intake Associated With the Development of Prostate Cancer?
Early Detection of Aggressive Prostate Cancer: Urine-Based Multibiomarker Test Under Study
AR-V7–Positive Prostate Cancer: Phase II Trial of Combination Immunotherapy
PSA Testing Versus MRI or Ultrasonography in Detecting Clinically Significant Prostate Cancer
Bipolar Androgen Therapy Versus Enzalutamide in Castration-Resistant Prostate Cancer
Updated ASCO Guideline: First-Line Management of Advanced Prostate Cancer
Stereotactic Body Radiotherapy for High-Risk Localized Prostate Cancer
Capivasertib Plus Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
Effect of Androgen-Deprivation Therapy on Systemic Symptomatology in Men With Prostate Cancer
Initial Systematic Biopsy Versus MRI for Detection of Clinically Significant Prostate Cancer
Plasma Cells and Immune Responsiveness in Black Men With Prostate Cancer
Active Surveillance for Early-Stage Prostate Cancer: Risk Factors for Metastases
Quality-of-Life Comparisons for Two Radiotherapies for Localized Prostate Cancer
Does Delaying Surgery Affect Outcomes in Localized High-Risk Prostate Cancer?
Do GnRH Agonists for Prostate Cancer Increase Risks for Dementia and Parkinson’s Disease?
Novel Clinical Prognostic Stage Group System for Prostate Cancer
Variable Regional Adoption of Genomic Testing for Prostate Cancer
Does Warfarin Exposure Decrease the Risk for Prostate Cancer?
Link Between Coffee Consumption and Risk for Prostate Cancer?
Conventionally Fractionated Versus Ultrahypofractionated Radiotherapy in High-Risk Localized Prostate Cancer
Salvage Radiotherapy for Prostate Cancer: Is Elevated PSA After Surgery Linked to Poor Outcomes?
Radiotherapy for Men With Prostate Cancer: Consider History of Medication Allergies
SIRT3 Expression in Metastasis of Prostate Cancer to the Bone
Emerging Role of Hemigland Cryoablation With MRI-Guided Biopsy for Prostate Cancer
Neoadjuvant Chemohormonal Therapy With Radical Prostatectomy for Localized Prostate Cancer
Current Perspective on Management of Advanced Prostate Cancer: ‘Abundance of First-Line Options’
Racial Disparities in Prostate Cancer Deaths: Potential Contributing Factors
Conservative Management of Prostate Cancer in Veterans: Racial Comparison
Is BMD Testing After Treatment for Prostate Cancer Meeting Guideline Recommendations?
Expert Panel Offers Practical Guide for Managing Castration‐Resistant Prostate Cancer
Does Androgen-Deprivation Therapy for Prostate Cancer Increase Risk of Dementia?
Enzalutamide Treatment for Prostate Cancer: Still Beneficial After Disease Progression?
Adjuvant Radiotherapy Versus Early Salvage Radiotherapy in Localized Prostate Cancer
Update on Trends in Initial Management of High-Risk Prostate Cancer
Prostate Cancer and Type 2 Diabetes: Focus on Outcomes and Metformin
Can Prostate Cancer Surveillance Be Tailored to Individual Risk?
Preradiation Testosterone Levels and Aggressiveness of Prostate Cancer
Mediterranean Diet and Prostate Cancer–Related Fatigue
Radiotherapy for Localized Prostate Cancer: Is Event-Free Survival Suitable Surrogate for Overall Survival?
Rucaparib in BRCA-Mutant Metastatic Prostate Cancer: TRITON2 Trial
Long-Term ADT for Prostate Cancer: Cognitive Function and Decision-Making
Updated ESMO Guidelines for Management of Prostate Cancer
Ultrahypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer
African Ancestry–Specific Variant May Be Linked to Familial Prostate Cancer Risk
First-in-Human Phase I Trial of Novel Vaccine in Metastatic Prostate Cancer
Surgery Versus Multimodal Radiotherapy for High-Risk Localized Prostate Cancer
Docetaxel Plus ADT in Minority Patients With Prostate Cancer
Does Radium-223 Improve Survival in Older Men With Metastatic Castration-Resistant Prostate Cancer?
Study Finds Regional Variations in Race-Based Survival Differences in Prostate Cancer
PSMA PET-CT Versus Conventional Imaging for Aggressive Prostate Cancer
Does Relugolix Reduce Testosterone Levels in Men With Advanced Prostate Cancer?
Adding Docetaxel to Standard Treatment of Localized High-Risk Prostate Cancer
PARP Inhibition in Men With Resistant Prostate Cancer
Can PSA Levels Before Salvage Radiotherapy Predict Outcomes in Men With Prostate Cancer?
Urinary Biomarkers in Detection of Prostate Cancer
Is ADT Protective Against SARS-CoV-2 Infection in Men With Prostate Cancer?
Conventional Fractionated Versus Hypofractionated Radiation for Prostate Cancer: A 10-Year Update
Height/Weight in Early Adulthood and Risk of Prostate Cancer
Concurrent Enzalutamide, Salvage Radiotherapy, and ADT in High-Risk Prostate Cancer
Link Between Polypharmacy and Inpatient Hospitalization in Older Patients With Prostate Cancer?
Racial Differences in Telomere Length in Prostate Cancer Cells
Can Tomato Consumption Reduce the Risk of Prostate Cancer?
Could a Low-Carb Diet Improve PSA Levels in Prostate Cancer?
Is Testosterone-Related Genetic Variant Linked to Poor Outcomes in Men With Prostate Cancer?
Comparing Radiation Therapies for Gleason 5 Prostate Cancer
Combined Biopsy Approach to Prostate Cancer Detection
Comparing Radiotherapies for Nodal Oligorecurrent Prostate Cancer
Salvage Radiotherapy Plus Androgen Deprivation After Surgery for Prostate Cancer
Risk of New Persistent Opioid Use After Minor Urologic Procedures
Neural Transcription Factor: Driver for Castration-Resistant Prostate Cancer?
Adverse Reactions to Treatments of Localized Prostate Cancer: A 5-Year Study
Artificial Intelligence and the Detection and Grading of Prostate Cancer
Do Genomic Markers Correlate With Subclassification of High-Risk Prostate Cancer?
Early-Phase Study of Antibody-Drug Conjugate in Castration-Resistant Prostate Cancer
Can Statins Lower the Risk of Aggressive Prostate Cancer?
Novel Biomarker for Early Prostate Cancer Under Study
Prospective Implications of BRCA Mutations in Prostate Cancer
Does Adjuvant Docetaxel Improve Biochemical Disease–Free Survival in Prostate Cancer?
Circulating Tumor DNA in Localized and Advanced Prostate Cancers
Study Finds Conservative Management of Prostate Cancer Varies Among Group Practices
Study Explores Link Between Diet and Prostate Cancer Risk
Use of Complementary and Alternative Medicine in Patients With Prostate Cancer
Updated Results From SPARTAN Trial on Apalutamide in Prostate Cancer
Small Cell Carcinoma of the Prostate: Update on Patterns of Care
Comparison of Radiation Therapies for Prostate Cancer Based on Quality of Life
Comparing Adjuvant and Early Salvage Radiotherapy for Prostate Cancer After Surgery
Insurance and Mortality in Prostate and Other Cancers
Incident Risk of Prostate Cancer and Mushroom Consumption
Comparing Imaging Modalities in Detecting Biochemical Recurrence of Prostate Cancer
Enzalutamide/ADT in Metastatic Hormone-Sensitive Prostate Cancer: ARCHES Trial
Should Stereotactic Body Radiation Therapy Be Standard Option in Localized Prostate Cancer?
Does Radical Prostatectomy Affect Sexual Interest and Satisfaction?
Cardiovascular Effects of Androgen-Deprivation Therapy in Prostate Cancer
Ultrahypofractionation Versus Conventional Fractionation in Prostate Cancer
Including Pelvic Lymph Nodes in Radiation Fields for Advanced Prostate Cancer: Update on Toxicity
Preventing Skeletal Fractures in Patients Treated for Metastatic Prostate Cancer
World Trade Center First Responders: Cause of Increased Risk of Prostate Cancer Explored
Can Repeated PSA Screening Reduce Prostate Cancer Mortality?
Inguinal Hernia After Minimally Invasive Radical Prostatectomy
LATITUDE Trial: Final Survival Data on Abiraterone Acetate and Prednisone Plus ADT
Radiotherapy After Prostatectomy: Updated Joint Clinical Guidance by ASTRO and AUA
Adding Docetaxel to Standard Treatment in High-Risk Prostate Cancer
Is There an Association Between Black Race and Mortality From Prostate Cancer?
Neoadjuvant Hormone Therapy Before Prostatectomy in Locally Advanced Prostate Cancer
Study Finds Docetaxel May Benefit Some Patients With Prostate Cancer
Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis
AR-V7 Assays and Treatment Outcomes in Castration-Resistant Prostate Cancer
Combining Approved Treatments in Metastatic Castration-Resistant Prostate Cancer
Viral Vector–Based Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Duration of ADT With Radiation After Prostatectomy Depends on Risk Factors
Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer
ARAMIS Trial: Darolutamide in Nonmetastatic Prostate Cancer
Risk of Dementia From Androgen-Deprivation Therapy for Prostate Cancer
LATITUDE Trial: Survival Benefit With Combination Therapy for Prostate Cancer
Lipid-Lowering Medication and Risk of Prostate Cancer
Active Surveillance vs. Radical Treatment of Prostate Cancer
Impact of Race on Survival in Metastatic Castration-Resistant Prostate Cancer
Androgen-Deprivation Therapy for Prostate Cancer: Managing Cardiovascular Risks
Health-Related Quality of Life in Men With Advanced Versus Localized Prostate Cancer
Computer-Simulated Study Suggests Enlarged Prostate May Actually Hinder Tumor Growth
Is Time to Biochemical Failure a Surrogate Endpoint in Locally Advanced Prostate Cancer?
Duration of Androgen Suppression and Zoledronic Acid in Locally Advanced Prostate Cancer
Does Apalutamide Negatively Impact Quality of Life in Nonmetastatic CRPC?
AUA Guideline Amendment for Castration-Resistant Prostate Cancer
Closer Look at Types of Prostatectomy and Quality of Life
Does Androgen-Deprivation Therapy Increase Risk of Heart Failure in Men With Prostate Cancer?
Can Tyrosine Kinase Inhibitors for CML Affect PSA Titers Unrelated to Prostatic Disease?
Assessing Combination of Osteoprotective Agents and Anticancer Drugs in Prostate Cancer
Early Research on Birabresib in Prostate Cancer and Other Solid Tumors
Noninvasive Diagnosis of Prostate Cancer Using Novel Imaging Technique
Long-Term Results With Hormonal Therapy Plus Radiotherapy in Prostate Cancer
Active Surveillance for Prostate Cancer: Are Patients Being Lost to Follow-up?
PSA Screening for Prostate Cancer: Does It Really Reduce Disease-Specific Mortality?
Coffee Consumption and Disease-Free Progression in Patients With Localized Prostate Cancer
Are Researchers Closer to Diagnosing Aggressive Prostate Cancer at an Early Stage?
Rebiopsy for Prostate Cancer: Can Some Men With Negative MRI Avoid It?
Does Enzalutamide Affect Metastasis-Free Survival in Men With Aggressive Prostate Cancer?
Can Hypofractionated Radiotherapy Improve Prostate Cancer Control?
Low Free Testosterone Concentration May Equal Low Prostate Cancer Risk
Survival Impact of Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Does Surgical Technique Affect Outcomes in Patients With Prostate Cancer?
New Prognostic Imaging Biomarker in Metastatic Prostate Cancer
Report Sheds Light on Trends in Prostate Cancer
Pharmacoeconomic Implications of Low-Dose Abiraterone in Castration-Resistant Prostate Cancer
Predictors of Urinary Function After Prostatectomy
Updated USPSTF Screening Guidelines for Prostate Cancer
Timing of Catheter Removal After Robot-Assisted Radical Prostatectomy
Clinical Associations of Luminal and Basal Subtyping in Prostate Cancer
ASCO Clinical Practice Guidelines for Metastatic Noncastrate Prostate Cancer
Robot-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer
Dose-Escalated Radiation Therapy for Intermediate-Risk Prostate Cancer
After Disease Progression on Enzalutamide, Can Bipolar Androgen Therapy Make a Difference in Prostate Cancer?
SPARTAN Trial: Apalutamide in Nonmetastatic Prostate Cancer
Radiotherapy Versus Surgery for High-Risk Localized Prostate Cancer
Health-Related Quality of Life After Radical Prostatectomy

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.